[Correspondence] Standardising MET amplification testing: limitations of the GCN ≥6 criterion – Authors' reply

We thank Yuxin Liu and colleagues for their interest in the KUNPENG study and concur that a clinically meaningful MET amplification cutoff is crucial to trial design and interpretation.1 Indeed, our selection of a gene copy number (GCN) of six or higher assessed by fluorescence in-situ hybridisation (FISH) was grounded in a biological rationale and clinical precedent. Mechanistically, MET amplification…